# Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia

> **NCT02828592** · PHASE2 · RECRUITING · sponsor: **Northside Hospital, Inc.** · enrollment: 20 (estimated)

## Conditions studied

- Severe Aplastic Anemia

## Interventions

- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide
- **RADIATION:** Total Body Irradiation
- **DRUG:** Rabbit ATG
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT02828592
- **Lead sponsor:** Northside Hospital, Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2016-09-09
- **Primary completion:** 2027-08-31
- **Final completion:** 2028-08-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02828592

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02828592, "Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02828592. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*